Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations between cannabis use, cannabis use motivations and past year polysubstance use among people living with HIV in Florida.

AIDS care·2026
Same author

Examining the Psychometric Properties of a Revised 40-Item Berger HIV Stigma Scale.

AIDS and behavior·2025
Same author

Statin Effects on Pericoronary Adipose Tissue Density in People With HIV: Insights From the REPRIEVE Trial.

JACC. Cardiovascular imaging·2025
Same author

Identifying Factors Associated With HIV Viral Suppression and Health Care Outcomes in the Florida Cohort Study Wave 3: Protocol for a Prospective Cohort Study.

JMIR research protocols·2025
Same author

Terrestrial dimethyl sulfide: Template for astrobiology.

Bioinformation·2025
Same author

Evaluating Cross-Sectional Associations Between Cannabis Use and Prospective Memory in People with HIV.

AIDS and behavior·2025

Related Experiment Video

Updated: Jun 18, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Abacavir and lamivudine combination.

Charurut Somboonwit1, Don Kurtyka, Ana Paula Velez

  • 1University of South Florida College of Medicine, Division of Infectious Diseases and International Medicine, Tampa, FL, USA.

Expert Opinion on Drug Metabolism & Toxicology
|November 26, 2009
PubMed
Summary
This summary is machine-generated.

Fixed-dose abacavir-lamivudine combinations improve adherence for HIV treatment. While generally effective and safer with genetic testing, caution is advised for cardiovascular events and in co-infected patients.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jun 18, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Area of Science:

  • Antiretroviral therapy
  • HIV/AIDS management
  • Pharmacology

Background:

  • Fixed-dose combinations (FDC) of antiretroviral drugs, such as abacavir and lamivudine, offer improved patient adherence by reducing pill burden.
  • Abacavir and lamivudine are established nucleoside reverse-transcriptase inhibitors available as a convenient once-daily FDC.
  • Current guidelines often position abacavir as an alternative due to concerns about cardiovascular events and efficacy in patients with high baseline viral loads.

Purpose of the Study:

  • To review clinical trial and cohort data on the efficacy, safety, and tolerability of abacavir, lamivudine, and their fixed-dose combination.
  • To synthesize findings regarding the use of abacavir-lamivudine in various patient populations and clinical scenarios.

Main Methods:

  • Systematic review of clinical trial data, post-marketing surveillance findings, and cohort studies.
  • Analysis of published clinical treatment guidelines for abacavir-lamivudine therapy.

Main Results:

  • Abacavir-lamivudine efficacy is well-established across numerous studies and is supported by treatment guidelines.
  • Genetic testing has significantly reduced the incidence of abacavir hypersensitivity reactions.
  • Conflicting data exists regarding cardiovascular event associations with abacavir; it's considered an alternative for high viral load HIV RNA (>100,000 copies/ml).

Conclusions:

  • Abacavir-lamivudine is an effective antiretroviral option, with safety profiles improved by genetic screening.
  • Careful monitoring of hepatic function is crucial for HIV/HBV co-infected patients discontinuing lamivudine to prevent severe hepatitis B exacerbations.
  • Abacavir's role as an alternative agent is supported, but cardiovascular event data requires further investigation.